<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04502316</url>
  </required_header>
  <id_info>
    <org_study_id>360059-001</org_study_id>
    <nct_id>NCT04502316</nct_id>
  </id_info>
  <brief_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction Registry</brief_title>
  <official_title>BAROSTIM THERAPY™ in Heart Failure With Reduced Ejection Fraction: A Post-Market Registry With the BAROSTIM™ NEO System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CVRx, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CVRx, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this registry is to provide additional evidence of the safety and benefit of&#xD;
      BAROSTIM THERAPY in the commercial setting in patients with heart failure with reduced&#xD;
      ejection fraction (HFrEF) that were recently implanted with the BAROSTIM NEO System.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Summary:&#xD;
&#xD;
      The CVRx BAROSTIM THERAPY in Heart Failure with Reduced Ejection Fraction (HFrEF) Registry&#xD;
      includes patients who have been recently implanted with the BAROSTIM NEO System for heart&#xD;
      failure. Up to 5,000 patients will be enrolled. Patients must be enrolled within 30 days&#xD;
      after the implant. Data should be obtained from standard of care measurements taken prior to&#xD;
      implant, at implant, and every six months after device implant, up to the 36-month visit at&#xD;
      which time each patient will be exited from the registry.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 26, 2020</start_date>
  <completion_date type="Anticipated">June 2028</completion_date>
  <primary_completion_date type="Anticipated">June 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of serious adverse events related to the system or implant procedure</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Serious adverse events related to the system or implant procedure through 36 months post-implant</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of heart failure hospitalizations</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Number of heart failure hospitalizations through 36 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of heart failure hospitalizations</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Duration of heart failure hospitalizations through 36 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change NYHA Classification</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Changes in NYHA Classification through 36 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in NT-proBNP</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Changes in NT-proBNP through 36 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in LVEF</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Changes in LVEF through 36 months post-implant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of arrhythmias</measure>
    <time_frame>36 months post-implant</time_frame>
    <description>Number and/or treatment of arrhythmias through 36 months post-implant</description>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Heart Failure</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BAROSTIM NEO™ System</intervention_name>
    <description>Implantation of the BAROSTIM NEO™ System</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The CVRx BAROSTIM THERAPY in Reduced Ejection Fraction (HFrEF) Registry will be performed&#xD;
        in patients with heart failure with reduced ejection fraction (HFrEF) that were recently&#xD;
        implanted with the BAROSTIM NEO System.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients can be included in the registry if they were implanted in the past 30 days&#xD;
             with a de novo BAROSTIM NEO System for the treatment of heart failure. Patients must&#xD;
             sign an IRB approved informed consent form for the registry to participate.&#xD;
&#xD;
        Indications:&#xD;
&#xD;
        The BAROSTIM NEO System is indicated for the improvement of symptoms of heart failure -&#xD;
        quality of life, six-minute hall walk and functional status, for patients who remain&#xD;
        symptomatic despite treatment with guideline-directed medical therapy, are NYHA Class III&#xD;
        or Class II (who had a recent history of Class III), have a left ventricular ejection&#xD;
        fraction ≤ 35%, a NT-proBNP &lt; 1600 pg/ml and excluding patients indicated for Cardiac&#xD;
        Resynchronization Therapy (CRT) according to AHA/ACC/ESC guidelines.&#xD;
&#xD;
        Contraindications:&#xD;
&#xD;
          -  Bilateral carotid bifurcations located above the level of the mandible&#xD;
&#xD;
          -  Baroreflex failure or autonomic neuropathy&#xD;
&#xD;
          -  Uncontrolled, symptomatic cardiac bradyarrhythmias&#xD;
&#xD;
          -  Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation&#xD;
             greater than 50%&#xD;
&#xD;
          -  Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic&#xD;
             evaluation&#xD;
&#xD;
          -  Known allergy to silicone or titanium&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Thomas Deering</last_name>
    <role>Study Chair</role>
    <affiliation>Piedmont Heart Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Bradley Knight</last_name>
    <role>Study Chair</role>
    <affiliation>Northwestern Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Larry Chinitz</last_name>
    <role>Study Chair</role>
    <affiliation>NYU Heart Rhythm Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Galle</last_name>
    <phone>763-416-2876</phone>
    <email>lgalle@cvrx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Grandview Medical Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandy Parker</last_name>
      <phone>205-971-7495</phone>
      <email>brandy_parker@grandviewhealth.com</email>
    </contact>
    <investigator>
      <last_name>Anil Rajendra</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chan Heart Rhythm Institute</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85206</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandi Hinojos</last_name>
      <phone>480-378-2440</phone>
      <email>sandi@chanheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Rodrigo Chan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Ramos</last_name>
      <phone>323-442-7983</phone>
      <email>Melissa.Ramos@med.usc.edu</email>
    </contact>
    <investigator>
      <last_name>Michael Fong</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orlando Heart and Vascular Institute</name>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <zip>32714</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Boone</last_name>
      <phone>407-767-7023</phone>
      <email>hbooone@heartorlando.com</email>
    </contact>
    <investigator>
      <last_name>Nandkishore Ranadive</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardiac Care Group</name>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <zip>33914</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony Giordano</last_name>
      <phone>239-574-8463</phone>
      <email>tgiordano@flccg.com</email>
    </contact>
    <investigator>
      <last_name>Joseph Freedman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Naples Heart Rhythm Specialists, PA</name>
      <address>
        <city>Naples</city>
        <state>Florida</state>
        <zip>34119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jori Richardson</last_name>
      <phone>239-263-0849</phone>
      <email>jrichardson@naplesheartrhytm.com</email>
    </contact>
    <investigator>
      <last_name>Kenneth Plunkett</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AdventHealth Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Millie Lopez</last_name>
      <phone>407-303-1578</phone>
      <email>millie.lopez@adventhealth.com</email>
    </contact>
    <investigator>
      <last_name>Hector Lozano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nevada Heart and Vascular Center</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Bracken</last_name>
      <phone>702-333-7273</phone>
      <email>aliciab@nevadaheart.com</email>
    </contact>
    <investigator>
      <last_name>Sanjay Malhorta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>DeGregorio Cardiology</name>
      <address>
        <city>Glen Ridge</city>
        <state>New Jersey</state>
        <zip>07028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Asad Cheema</last_name>
      <phone>973-743-1121</phone>
      <email>asadmc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Asad Cheema</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 30, 2020</study_first_submitted>
  <study_first_submitted_qc>August 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2020</study_first_posted>
  <last_update_submitted>June 28, 2021</last_update_submitted>
  <last_update_submitted_qc>June 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

